Updated findings from the ENZAMET trial show that adding enzalutamide to testosterone suppression offers clinically meaningful improvements in overall survival.
Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and better patient-reported quality-of-life.
Investigators observed a complete response in more than half of patients treated with tislelizumab plus nab-paclitaxel for high-risk NMIBC that was not completely resectable.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
Data suggest that 0.5% of patients with clinical stage I testicular cancer experience relapse after 10 years.
Short-term androgen deprivation therapy alone or in combination with pelvic lymph node radiotherapy can improve the efficacy of prostate bed radiotherapy.
Increases in waist-to-hip ratio, body mass index, waist circumference, and total body fat percentage were associated with increases in the risk of prostate cancer death.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The median time to definitive deterioration was longer with lenvatinib-pembrolizumab than with sunitinib.
Measuring lymphocytes during or after radiotherapy could provide useful information about infection risk, according to researchers.
